7 DAY TREATMENT WITH PANTOPRAZOLE, AMOXIC ILLIN AND METRONIDAZOLE FORCURE OF HELICOBACTER-PYLORI INFECTION

Citation
J. Glaser et al., 7 DAY TREATMENT WITH PANTOPRAZOLE, AMOXIC ILLIN AND METRONIDAZOLE FORCURE OF HELICOBACTER-PYLORI INFECTION, Medizinische Klinik, 93(2), 1998, pp. 65-69
Citations number
20
Categorie Soggetti
Medicine, General & Internal
Journal title
ISSN journal
07235003
Volume
93
Issue
2
Year of publication
1998
Pages
65 - 69
Database
ISI
SICI code
0723-5003(1998)93:2<65:7DTWPA>2.0.ZU;2-9
Abstract
Background: The present study was conducted to investigate the efficac y and tolerability of a 7-day treatment with pantoprazole, amoxicillin and metronidazole for the eradication of Helicobacter pylori (H. pylo ri) infection. Patients and Methods: Fifty patients (26 male, 24 femal e, age 18 to 86, mean 54 years) with an active duodenal (n = 25) or ga stric ulcer (n = 25) were recruited into the study, 48 patients being H. pylori positive at the study start. Patients were treated with pant oprazole (40 mg bid), amoxicillin (1 g bid) and metronidazole (500 mg bid) for 7 days and for another 21 days with pantoprazole (40 mg/od). Four weeks after the end of study medication the patients were re-exam ined endoscopically and their H. pylori status was re-assessed using u rease test, histology and C-13-urea-breath test. Results: In 39 of 48 intention to treat patients, H. pylori infection was cured, according to 81% (95%-CI = 67 to 91%). In the per protocol population in 35 of 4 1 patients H. pylori was eradicated, which results in an eradication r ate of 85% (95%-CI = 71 to 94%). Ulcer healing was endoscopically conf irmed in 45 of 48 patients (94%; 95%-CI = 83 to 99%) after 8 weeks. Si x of 50 patients (12%) reported mild to moderate probable side-effects of the study medication. Cure of the infection was associated with a distinct reduction of the gastritis grade and activity. Conclusion: A 7-day triple therapy using pantoprazole, amoxicillin and metronidazole is an effective and cost-effective alternative to regimens including clarithromycin for the treatment of H. pylori infection.